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There has been a progressive number of studies on the male hormone it was found 
to have protein anabolic function. Pre-and post-operative administration of S. C・7525
(4・esterene・3.＇ゴ， 17β司diol,17-dipropionate) was attempted on the patients who were under-
gone digestive tract surgery, because of its comparatively high potence of protein anabolic 
function to the androphanizing function. This report was concerned with the results. 
Cases and administration method : 
There 回 sesof gastric cancer, 3回 sesof gastric ulcer, 1 case of esophageal四 ncer
and l回 seof sigmoid colon回 ncerwere analyzed in contrast to the several回 sesof those 
corresponding diseases except the esophageal cancer, which were undergone the same degree 
of surgical attack. Intramuscular administration dosage of the S. C-7525 was 2 cc (50 
mg) during a week before and 7 cc (175 mg) during 3 weeks after the operation; 225 
mg for 4 weeks in total. Associated administration of amino acid was also done both 
pre‘and post-operatively. 
Results: 
Our cases. the cancer patients of digestive tract were marastic diseases in themselves 
and the surgical operation and the difficalty of the nutritional supply after it add furthere 
problems, be回 usethey cause the acceleration of the protein catabolism to waste the depot 
protein and secondarily the vicious effect on the rじじm·cr~＇. In such a case, the administra-
tion of the protein anabolic steroid is to be expected in order to inhibit the catabolism 
and also to utilize the import of nitrogen substances. 
The pre-and post-operatiw administration appears to prevent the waste of the body 
832 日本外科宝函第33巻第4号
protein ; decrement of body weight los and increment of serum protein were obviously 
obtained in the postoperative course. The increased A;G ratio is significant to show the 
normality of serum colloid reaction. Blood sedimentation rate was also regained. 
Although the protein anabolic steroid has been cheifly used in the field of the internal 
medicine, the usage is proposed in the surgical回 sesfor the early postoperative recovery. 
There was no side effect of S.仁 7525.
緒言
1935年 K配 hakian及び Muriin等の実験的研究に
より p 男性ホルモンに蛋白同化作用のあることが確認
されて以来，この方面に於ける研究はめぎましく，
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投与対象及び投与法
使用例は胃癌3例p 食道癌 l例， 8状結腸癌 1例p












































前 l週2管y 術後3週7管p 計9管の SC-7525を併










表1 SC:-75:!5 (1!'. f]例臨症成績総括
宮 ＇~： 病 名（検査時 l官？叩＇IUJ調糖尿［赤：ftI*i す｜白血球 1~~1 食列車 11
i I I I I I 1 I用 i
I 69 I 入院時！ 6.0 I 0.39 I （掛）｜（ー ） I 3so ! go 1 1 .600 I日 OI普通！ 十一
I i十！胃 癌 l術後 1週l1.1 I 0.42 I c時）同＋川 324I 92 ！附oI ｜減少｜（一）｜（＋）
i 0: ｜術後3週｜ 6.1 I 0.43 ! I僻 II （一川 420 95 1 .200 I 55.5 .普通｜
4 I l入院時 I6.o 1 o.91 1 cー）｜（ー ） I 422 79；問。I40.0 I普通｜ I 
2 I 1胃 癌｜術後1週 I6.2 I 0.95 I （ー ）｜（ー ） I 480 ! 82 I 8,300 I l普通｜（ー ） i ( +)
l合 ｜術後3週｜ 6.5 I 0.91 I cー）｜（ー ）｜ 453 80 j 仰 oI 38.o i充進｜ ！ 
134 I 1入院時 I5.1 I 0.74 I I ）ー （ー） I 450 r 48 1 4,800 5o.o 減少
6 I ｜胃 癌｜術後l週！ 5.6 I 0.81 I c +) I cー） I 402 I 45i 8,600 1 充進（ー I (-It) 
！合 I I i I I I I I I ； ｜ ｜ 3週｜ 5.9 I o.84 I cー）｜（ー ）｜ 363 I 47I 4刈0• 49.5 元進
441胃潰疹及び｜入院時 I6.9 , 0.80 1 cー〕｜（ー ） I 480 I 74 I 5 600 I削普通
7 I ｜十二指腸憩｜術後 I週 i5.8 , o.9o I cー）｜（ー ） I 422 I 10I 6,200 1 普通 （ー I • C+) 
合｜室 ｜術後2週 I1.0 , o.91 （ ）ー［（ー ） I 500 I 81 I弘400I則元進 : 
i 59! ！入院時 I6.8 ! 1.26 ! rー ）｜（ー）｜加 hooI問。I41.0 I普通
8 I 1胃泣疹｜術後 l週 I5.6 I 1.25 I Iー ）｜（ー ） I 330 I 68i 8,500 I l普通（ー） I +J 
合 I I I I I I I I I I ｜ 、 2週 7.4 I 1.28 I （ー ）｜（ー ） I 341 i 10 I 6,100 40.5 I普通
｜ ｜入院時 11.1 r 1.05 I （ー ）！（ー ） I 487 I 93 I山＇ 45.0 普通
9 1胃潰疹術後I週 I5.8 I 1.15 1 1ー）！（ー ） i 320 I 10 I 1 .800 , ：元進（ー）（掛）
合！ i I I i I i I I ' 7.5 I 1.07 IIー） Cー）｜ 337 75 I 4,300 -15.3 充進
58 ! （入院時 5.4 I 0.80 I I +) I （ー） I 465 60 I山 oo! 56.8 1著減！
13 ! s状結腸癌｜術後1週 5.9 I o.88 I cー） I c←） 428 I 78 I 8,300 I ｜普通！〔ー ） （＋） 
-'-0 i術後3週＇ 7.2 I 0.97 I I叶（ー） I 456 : 10 I 川 oI 60.2 I時r; 一寸~－ι円a ID示τ打ζ汀－4s5~~1-;.800－－－~s.-5－著減！ ｜ － 
15 ＇〔！食道癌 l術後1週 I6.3 i o.94 I cー〉｜（＋） 379 ; 72 8,300 i減少｜尿糖｜（＋）

























自立球減 少なく， f':t符、も 比較的早く改善し，体重l土
56.8kgから退院時 f29日目） 60.2kgと著明に初日：p
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｜入院時 7.1 48.8 1.6 7.0 12.8 24.4 9 45 合 I/ l術後18日 45.9 3.3 13.1 I 9.8 19.7 7.5 1.17 54.1 
l入院時 5.4 0.80 4 l.3 55.7 6.6 9.8 11.7 21.6 13 58 6 吋状結腸癒｜
7.0 0.97 -l.2 9.9 11.5 25.1 ｜術後3週
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胃癌術後尿量変化
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